Osmotin treatment modulates adiponectin receptor 1 (AdipoR1), induces AMP-activated protein kinase (AMPK)/Sirtuin 1 (SIRT1) activation and reduces SREBP2 (sterol regulatory element-binding protein 2) expression in AD models. Here, ADIPOR1 is linked to Alzheimer disease.